Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Taflinar

- PMLiVE

GSK discontinues development of Anacor antibiotic

Patients developed resistance to compound during trial

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

Shionogi-ViiV to file HIV drug dolutegravir for approval

GSK, Pfizer and Shionogi joint venture completes phase III trials programme

A new dogma in HTA assessment

New communication routes to HTA agencies are needed to ensure that these organisations can advise on clinical trial design

- PMLiVE

The bigger picture in medicine value

By focusing on cost are we obscuring the true value of medicines?

- PMLiVE

GSK’s Dr Brett Haumann takes up chief medical officer role at Circassia

Joins as UK biopharma prepares to move lead technology ToleroMune into phase III

- PMLiVE

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

Kai Gait returns to GSK as digital marketing director

He will be developing digital channel materials and services, built on customer insights

- PMLiVE

GSK’s Olympic doping facility to research personalised medicines after Games

MRC-NIHR Phenome Centre is “phenomenal legacy” from London 2012 says MRC’s Prof John Savill

GSK and other Olympic sponsors may face hacking attack

IT security firm claims ‘hacktivist’ network Anonymous could target websites of London 2012 partners

GSK pay $3bn to settle drug-marketing case

UK drug-maker pleads guilty for promoting a number of drugs in the US off-label

UK reaffirms NHS access to NICE-approved drugs

Health Secretary makes pledge on same day Future Forum recommendations on NHS reform accepted

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links